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Introduction
The prevention of communicable diseases is a public health priority and the primary goal of vaccine research. One promising strategy involves the use of antigen-encoding DNA plasmids to induce protective cellular and humoral immune responses against pathogenic viruses, parasites and bacteria. [1] [2] [3] [4] [5] [6] [7] DNA vaccines are composed of an antigen-encoding gene whose expression is regulated by a strong mammalian promoter expressed on a plasmid backbone of bacterial DNA. 8, 9 Although DNA vaccines have proven effective in mice, their immunogenicity in larger animals (including humans) appears to be more limited. 10 A number of approaches designed to improve the immunogenicity of DNA vaccines has been examined. We and others studied whether DNA plasmids encoding immunostimulatory cytokines can be used to improve the immunogenicity of a DNA vaccine. 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] For example, laboratories have examined the impact of plasmids encoding IL-1␣, IL-2, IL-4, IL-5, IL-10, IL-12, IL-15, IL-18, IFN␥, TNF␣, TGF␤ and GM-CSF 7, [12] [13] [14] [15] [16] [17] [18] [19] [20] on the response to a co-administered DNA vaccine. Although responses varied somewhat, plasmids encoding IFN␥ generally induced a Th1-biased response, characterized by increased antigen-specific IL-2 and/or IFN␥ and IgG2a production. Plasmids encoding IL-4 were found to stimulate a Th2-biased response, characterized by increased IgG1 production. 7 None of these studies reported serious side-effects associated with the administration of cyto-
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Whereas DNA vaccines induce an immune response capable of eliminating plasmid transfected cells, DNA plasmids encoding self proteins (such as cytokines) can persist and direct protein secretion for prolonged periods in vivo. 21, 22 Thus, cytokine-encoding plasmids may have long-term systemic effects on immune homeostasis, 21, 22 and thus potentially trigger immune deviation or the development of autoimmune disease. 21, 23 Since most vaccines are administered to newborns and youngsters, the administration of cytokine-encoding plasmids to children whose immune system is still maturing might result in permanent abnormalities in immune homeostasis. 24 To examine these safety concerns, we administered DNA plasmids encoding IL-4 (pIL-4) and IFN␥ (pIFN␥) to adult and newborn BALB/c mice. The cytokines encoded by these plasmids represent classic examples of Th2 and Th1 cytokines, respectively, and are known to be active in vivo. Our results indicate that both pIL-4 and pIFN␥ improve the host's immune response to a coadministered DNA vaccine. These plasmids altered the immune milieu and biased the maturation of Th0 cells, as reflected by changes in spontaneous and concanavalin A (Con A)-induced cytokine secretion. However, these effects were short-lived, were not associated with increased serum cytokine levels, did not alter the immune response stimulated by an unrelated antigen, and did not promote the production of pathogenic autoantibodies. Thus, findings suggest that cytokine-encoding plasmids may be safe when co-administered with conventional DNA vaccines.
Results
In vivo activity of cytokine-encoding DNA plasmids BALB/c mice were injected i.m. with plasmids encoding IL-4 or IFN␥. mRNA was isolated from the site of injection and analyzed by RT-PCR to determine whether the plasmids were being actively transcribed in vivo. As seen in Figure 1 , IFN␥ mRNA was present at 2 and 5 weeks after plasmid administration, whereas IL-4 mRNA was present at 2 weeks but was undetectable by 5 weeks after injection. By comparison, plasmid DNA was present at the site of injection for Ͼ5 weeks (data not shown). No cytokine mRNA was present in the muscle beds of vector-treated control mice (shown as negative control in Figure 1 ) nor was cytokine mRNA present in the contra lateral muscle bed (data not shown). Despite evidence of ongoing gene transcription, protein secretion by transfected cells was insufficient to alter serum cytokine levels (data not shown).
pIL-4 and pIFN␥ act as immune adjuvants
To confirm that cytokine-encoding plasmids can act as immune adjuvants, mice were co-immunized with pCSP (a plasmid encoding the circumsporozoite protein of malaria) plus pIL-4 or pIFN␥. As seen in Table 1 , vaccination with pCSP alone stimulated the production of IgG anti-CSP antibodies (titer 1:32). We then compared the production of IgG1 versus IgG2a anti-CS.1 antibodies, since the secretion of these isotypes is influenced by IL-4 and IFN␥ levels, respectively. 25, 26 pCSP alone induced an anti-CS.1 response whose IgG1:IgG2a ratio was 3.0. Co-administration of pCSP with pIL-4 boosted IgG1 anti-CSP antibody production by nearly 30-fold, resulting in an IgG1:IgG2a ratio of 43. Co-administration of pIFN␥ with pCSP preferentially boosted IgG2a anti-CSP production (IgG1:IgG2a ratio of 1.3) and significantly increased the IgG anti-CSP Ab titers; Table 1 ). Co-admin- istration of cytokine-encoding plasmids with pCSP did not significantly alter IgM or IgA anti-CSP antibody production (data not shown).
The ability of pIFN␥ and pIL-4 to improve the immune response induced by pCSP indicated that the co-administration of these plasmids might promote protective immunity in BALB/c mice. We therefore challenged vaccinated mice with 100 live Plasmodium yoelii sporozoites. As shown in Figure 2 , only 25% of mice vaccinated with pCSP alone were protected from infection, whereas 55% of mice vaccinated with pCSP plus IL-4 or IFN␥ were protected (P = 0.026). The effect of pIL-4 and pIFN␥ on the immune milieu is short-lived To examine whether cytokine-encoding plasmids had a systemic effect on immune activity, the number of cells actively secreting Th1 and Th2 cytokines was monitored using an ELIspot assay. Two weeks after injection, pIFN␥ stimulated a significant increase in the number of spleen cells producing the Th1-associated cytokines IFN␥ (3.7-fold) and IL-2 (29-fold) ( Figure 3a ). This effect on IFN␥ secreting cells is consistent with the observed stimulation of IgG2a anti-CSP secreting B cells in these mice (Table  1) . No significant effect on cells secreting IL-4, IL-6, IL-10 or IL-12 was detected in pIFN␥-treated animals (data not shown). When Con A was used to stimulate resting T cells from these mice, the number of lymphocytes secreting IFN␥ was increased nine-fold while the number secreting IL-2 was increased three-fold over controls ( Figure 3b ). These findings suggest that pIFN␥ may facilitate the maturation of Th0 into Th1 cells. This effect was short-lived, however, since no alteration in the frequency of IFN␥ producing cells was present 5 weeks after plasmid administration. Similarly, adult mice injected four times with pIFN␥ had normal numbers of cells secreting Th1 and Th2 cytokines 5 weeks after the final treatment ( Figure 3 ).
Administration of pIL-4 had a modest effect on the number of splenocytes spontaneously secreting IL-4 in vivo (Figure 3a ), but no effect on the number of cells secreting IL-2, IL-6, IL-10, IL-12 or IFN␥ at any time-point examined (data not shown). Similarly, pIL-4 induced a modest increase in the number of cells stimulated by Con A to secrete IL-4, suggesting that this plasmid induced the maturation of Th0 into Th2 cells. As above, these effects were observed 2 weeks but not 5 weeks after pIL-4 administration, and did not persist despite when pIL-4 was administered repeatedly to adult mice ( Figure 3 ). Mice treated with control plasmids had normal numbers of cytokine secreting cells at 2 and 5 weeks. 
Effect of cytokine-encoding plasmids on subsequent immune responses
We were interested in examining whether cytokine-encoding plasmids would alter an animal's subsequent response to a novel antigenic stimulus. BALB/c mice pretreated with pIL-4 or pIFN␥ were immunized 6 weeks later with 2,4,6-trinitrophenylated (TNP)-OVA in complete Freund's adjuvant (CFA) or TNP-BA. These antigens were selected because they were known to preferentially induce Th2 and Th1 responses, respectively. 27 Two weeks after immunization, the antibody and cytokine profile elicited by immunization was analyzed. Consistent with earlier studies, TNP-OVA/CFA preferentially activated IL-4 secreting cells (resulting in a low IFN␥:IL-4 secreting cell ratio, Figure 4a) , and the production of IgG1 anti-TNP antibodies (Figure 4b ). In contrast, TNP-BA primarily stimulated the production of IFN␥ and IgG2a anti-TNP Abs (Figure 4a and b) . No significant difference in these activation parameters was observed in mice previously injected with pIL-4 or pIFN␥ (Figure 4 ).
Effect of cytokine-encoding plasmids on the neonatal immune system
We reasoned that if cytokine-encoding plasmids altered immune homeostasis, this effect would be most evident in newborn animals whose immune system was still maturing. Therefore 50 g of cytokine-encoding plasmid was administered to BALB/c mice at 2 and 10 days of age. Five weeks after the second treatment, spontaneous and Con A-induced cytokine production was monitored by ELIspot assay.
As seen in Figure 5 , neonatal administration of pIFN␥ significantly increased the number of spleen cells spontaneously secreting IL-2 and IFN␥ at the 5 weeks timepoint. pIFN␥ also increased the frequency of resting T cells that responded to Con A stimulation by secreting IFN␥. These changes were of similar magnitude to those observed in adult mice. pIL-4 had no discernable effect 
Figure 5 Cytokine-encoding plasmids influence the cytokine profile of newborn mice. Newborn BALB/c mice were treated at 2 and 10 days of age with 50 g of pIL-4 (`) or pIFN( (˾). At 6 weeks, cytokine production by spleen cells was analyzed by ELIspot assay. Data represent the mean ± s.d. of IL-2, IL-4 and IFN␥ secreting cells/10 6 splenocytes (three mice per group). *P Ͻ 0.05 when compared to the PBS treated group (२).
on cytokine producing cells in neonatal mice, nor did pIL-4 or pIFN␥ effect the number of cells secreting IL-6, IL-10 or IL-12 (data not shown).
Mice treated twice with pIL-4 or pIFN␥ as newborns were immunized at 6 weeks of age with the TNP conjugates used above. As seen in Figure 6 , these animals mounted normal responses to TNP-OVA/CFA and TNP-BA. No bias in either their cytokine or IgG anti-TNP response was detected.
Effect of cytokine-encoding plasmids on serum IgG anti-DNA production Previous studies showed that DNA vaccines induce a short-lived increase in the number of B cells actively secreting IgG anti-DNA autoantibodies in vivo. Consistent with that observation, multiple administrations of the control plasmid pCSP induced a modest increase in serum IgG anti-DNA antibody levels ( Figure 7) . However, this effect was not magnified by the administration of pIL-4 or pIFN␥.
Discussion
Vaccine development is an important goal of biomedical research. The simplicity and cost-effectiveness of DNA vaccines has sparked considerable interest in this form of immunization. [1] [2] [3] [4] [5] [6] [7] Unfortunately, ongoing human trials suggest that the immunogenicity of DNA vaccines may be limited. 10 To overcome this constraint, cytokine-encoding DNA plasmids have been used as 'genetic adjuvants' to boost the response to a co-administered DNA vaccine. 11 However, little information is available on the safety or long-term systemic effects of cytokine-encoding plasmids. 28 To gather such information, we treated mice
Figure 6 Effect of neonatal administration of cytokine-encoding plasmids on subsequent cytokine and antibody production. BALB/c mice were treated with pIL-4 (`) or pIFN␥ (˾) and immunized with TNP-OVA or TNP-BA as described in the legend to Figure 6. (a) The ratio of IFN␥:IL-4 secreting cells was determined ELIspot assay 2 weeks after immunization. Plasmid exposure had no significant effect on subsequent immune reactivity. (b) IgG1 and IgG2a anti-TNP antibody titers were monitored in mice treated as described above. Plasmid exposure had no significant effect on subsequent immune reactivity.
with plasmids encoding prototypic Th1 and Th2 cytokines (IFN␥ and IL-4, respectively), both of which contribute to the maturation of naive T cells. 29 Our findings confirm that these plasmids improve the immune response elicited against a co-administered DNA vaccine. Moreover, we found that these plasmids have systemic effects on the host's immune system, altering the Th1:Th2 ratio in vivo. Yet these effects were short-lived, did not alter immune reactivity against unrelated antigens, and did not lead to the development of autoimmunity in adult or newborn mice.
A number of laboratories have investigated the ability of cytokine-encoding plasmids to enhance vaccine-specific immune responses in vivo. 7, [12] [13] [14] [15] [16] [17] [18] [19] [20] Results indicate that several different cytokine-encoding plasmids improve and/or modulate the strength and nature of the immune response elicited by a co-administered DNA vaccine. In our studies, both pIL-4 and pIFN␥ enhanced the IgG antibody and cytokine response induced by the pCSP DNA vaccine. Co-administration of pIFN␥ biased the anti-CSP response towards IgG2a antibodies, while pIL-4 biased the response towards IgG1 antibody production (Table  1) . Previous studies indicate that IgG antibodies as well as IFN␥-secreting CD8 + T cells can confer protection against malaria infection. 30, 31 This may explain why both of these cytokine-encoding plasmids improved pCSP vaccine-induced host resistance to sporozoite challenge, despite differences in the type of immune response they elicited (Figure 3) .
Both cytokine-encoding plasmids also had systemic effects on recipient mice. The total number of spleen cells spontaneously secreting IL-2 and IFN␥ rose significantly after pIFN␥ administration, while the number secreting IL-4 increased after delivery of pIL-4 ( Figure 3 ). Plasmid injection also altered the number of spleen cells that responded following polyclonal Con A stimulation, consistent with an effect on the maturation of Th0 into Th1 or Th2 cells. This effect, shown on spleen cells in Figure  3 , was also observed among lymph node cells from these animals (data not shown). When the effect of these cyto-kine-encoding plasmids was examined in neonatal mice, pIFN␥ again stimulated increased IFN␥ and IL-2 secretion, while pIL-4 had no detectable effect on the maturing repertoire. This constellation of findings suggests that pIFN␥ and pIL-4 can affect the maturation of Th0 into Th1 and Th2 cells in vivo, as well as act as local immune adjuvants.
Despite these short-term effects on the immune milieu, pIL-4 and pIFN␥ did not alter serum cytokine levels, nor did they induce long-term changes in Th cell homeostasis even when administered multiple times to newborn or adult mice. For example, mice challenged with TNP-BA or TNP-OVA/CFA 6 weeks after the fourth injection of plasmid mounted an immune response indistinguishable from that of normal controls. Similarly, the antigen-specific responsiveness of young mice was not altered by the administration of cytokine-encoding plasmids during the neonatal period. These findings suggest that the adjuvant-like properties of pIL-4 and pIFN␥ are short-lived, being characterized by a transient shift in the frequency of Th1:Th2 secreting cells. Of note, pIL-4 had less activity than pIFN␥, perhaps reflecting differences in the relative strength of the immune stimulation induced by these two cytokines. Alternatively, it is possible that pIFN␥ synergizes with the Th1 stimulatory effects of unmethylated CpG motifs present in the backbone of these plasmids. 8, 9 Indeed, previous studies show that CpG motifs in the plasmid backbone of DNA vaccines can trigger an increase in the production of IgG anti-DNA autoantibodies. 23 Analysis of serum antibody levels showed that autoantibody production was not magnified by the use of cytokine-encoding plasmids. Thus, our studies suggest that these prototypic Th1 and Th2 cytokine-encoding plasmids can improve the immunogenicity of DNA vaccines without inducing harmful or long-term alterations in the immune milieu.
Materials and methods
Reagents DNA plasmids encoding murine IL-4 (pSG5IL4, referred to here as pIL-4, a kind gift of Dr HC Ertl, Wistar Institute, Philadelphia, PA, USA), IFN␥ (VR2103, referred to as pIFN␥) and the entire coding region of the circumsporozoite protein of malaria (VR2507, referred to as pCSP, both gifts of Vical, San Diego, CA, USA), as well as their respective vectors (pSG5 or VR1012) were purified from transformed DH5alpha competent cells using an Endofree Plasmid Maxi Kit (Qiagen, Santa Clarita, CA, USA). Endotoxin concentrations were uniformly below 0.1 endotoxin units (EU)/mg, as determined using a Limulus amebocyte lysate (LAL) assay (Bio-Whittaker, Walkersville, MD, USA). 2,4,6-Trinitrophenylated ovalbumin in complete Freund's adjuvant (TNP 40 -OVA/CFA) and TNP-Brucella abortus (TNP-BA) were prepared as previously described. 27 CS.1 protein, a PyCSP-derived immunoaffinity-purified fusion protein produced in Escherichia coli, and consisting of amino acids 64-321 of the intact PyCSP protein fused to 81 AA of the nonstructural protein of influenza A, was used for detecting serum anti-CS.1 antibody responses. 32 In vivo experimental treatments Female BALB/c mice were bred and maintained in our specific pathogen-free animal colony. Adults were immunized at 6 weeks of age in the right quadriceps muscle and boosted at 12, 13, 14 weeks of age with 50-100 g of cytokine-encoding plasmid and/or pCSP in 50 l of sterile PBS. In some experiments, mice treated with cytokineencoding plasmids were immunized at 20 weeks of age with 100 g of TNP-OVA emulsified in CFA or with 50 l of TNP-BA containing 10 9 heat-killed organisms i.p. Newborn BALB/c mice were inoculated i.m. at 2 and 10 days of age with 50 g of the cytokine-encoding plasmids. At 6 weeks of age, they were immunized as described above with TNP-OVA or TNP-BA. Mice were periodically bled from the tail vein, and serum stored at −20°C until analysis. At various times after these treatments, mice were killed by cervical dislocation and their spleen, mesenteric lymph nodes and quadriceps muscles removed for cytokine ELIspot and RT-PCR assays. All studies utilized at least three mice per group, and each animal was analyzed independently.
Sporozoite infection
Three weeks after the second pCSP immunization mice were challenged by intravenous injection with 100 P. yoelii sporozoites. 17 To document malaria infection, Giemsastained blood films were examined on days 7, 11 and 14 days after challenge. The presence of у1/1000 infected RBC at any time was taken as evidence of active infection. Statistical analysis was calculated by the 2 test using a 2 × 2 table.
PCR
Tissue samples were removed at 2 and 5 weeks after administration of cytokine-encoding plasmids and flash frozen in liquid nitrogen. The tissue was homogenized and DNA or total RNA was extracted using TRIzol (Gibco BRL, Gaithersburg, MD, USA). Total RNA was incubated with DNase I (Boehringer Mannheim, Mannheim, Germany) to remove contaminating cDNA. SuperScript II transcriptase (Life Technologies, Gaithersburg, MD, USA) was used with random hexamer priming to prepare cDNA from total RNA. Oligonucleotide primers were prepared from the 5Ј-ACAAAAAT CACTTGAGAGAGATCAT (sense) and 5Ј-AGTAA TCCATTTGCATGATGCTCTT (antisense) coding regions of the IL-4 plasmid, and from the 5Ј-GAAAGCC TAGAAAGTCTGAATAACT (sense) and 5Ј-ATCAGCA GCGACTCCTTTTCCGCTT (antisense) coding regions of the IFN␥ plasmid, as previously described. 33 Primers for the 5Ј-GACATGGAGAAGATCTGGCACCACA (sense) and 5Ј-ATCTCCTGCTCGAAGTCTAGAGCAA (antisense) coding region of mRNA for mouse ␤-actin were included as controls. A 35-cycle PCR was performed on the DNA or cDNA samples using Taq DNA polymerase (Promega, Madison, WI, USA). Each cycle consisted of degeneration at 94°C for 60 s, annealing at 60°C for 90 s, and extension at 72°C for 90 s. Amplified products were analyzed by electrophoresis through a 2% agarose gel and visualized by ethidium-bromide staining.
Antigen-specific ELISA assays ELISA assays were performed to determine the concentration of serum anti-CS.1, anti-DNA, anti-OVA and anti-TNP antibodies present in immunized mice. Briefly, 96-well Immulon 1 plates (Dynatech Laboratories, Chantilly, VA, USA) were coated with 10 g/ml of TNP 26 -KLH, CS.1 protein, ovalbumin or calf thymus DNA (Sigma Diagnostics, St Louis, MO, USA) in carbonate buffer and then blocked with PBS 1% BSA. The plates were overlaid with serially diluted serum, washed, and reacted with phosphatase-conjugated anti-mouse IgG, IgG1 or IgG2a antibodies (Southern Biotechnology Associates, Birmingham, AL, USA). Relative antibody concentrations were obtained in a colorimetric assay by comparison to a standard curve generated using high titrated antigenspecific anti-sera.
Cytokine-specific ELIspot and ELISA assays 96-Well Immulon 2 plates were coated with anti-IL-2 (18161D, Pharmingen, San Diego, CA, USA), anti-IL-4 (MM450C; Endogen, Woburn, MA, USA), anti-IL-6 (18071D; Pharmingen), anti-IL-10 (18141D; Pharmingen), anti-IL-12 (18480D; Pharmingen) or anti-IFN␥ (AMC-4834; Bio-source, Camarillo, CA, USA) in PBS (pH7.2) buffer for 4 h at room temperature as described. 34 The plates were blocked with PBS-5% BSA for 2 h and washed with PBS-0.025% Tween 20. A single suspension of lymphocytes was prepared in sterile RPMI 1640 supplemented with 5% FCS and added to anti-cytokinecoated plates at a starting concentration of 1 × 10 6 cells per well. Plates were incubated at 37°C for 6 h in a 5% CO 2 in air incubator. Plates were washed, and then treated with biotinylated anti-cytokine antibody followed by phosphatase-streptavidin (Pharmingen), as described. 34 ELIspots developed after the addition of BCIP phosphatase (Sigma Diagnostics) in agarose, and visually quantified. ELISA assays for quantifying serum cytokines were performed as described above, except serum rather than cells were added to anti-cytokine-coated plates.
